Key facts
- Zealand Pharma announced Phase 2 data for petrelintide.
- The data demonstrates durable weight loss.
- The study results indicate sustained efficacy in weight reduction.
Zealand Pharma has announced that Phase 2 data for its drug candidate, petrelintide, has demonstrated durable weight loss. The study results indicate that the drug has sustained efficacy in reducing body weight. This development marks a significant step in the clinical trial process for petrelintide, suggesting potential for long-term weight management benefits.